Wuxi Taxus Pharmaceutical Co., Ltd. is primarily engaged in the research, development, production, and sales of antitumor active pharmaceutical ingredients (APIs) and drug formulations. Its API products include Paclitaxel, Docetaxel, Cabazitaxel, Raltitrexed, and Carfilzomib, while its drug formulations encompass Paclitaxel injection, Docetaxel injection, Raltitrexed for injection, and Carfilzomib for injection.
Upholding the quality philosophy of "refined management and precise control", the company has established a high-standard GMP quality management system as well as an EHS (Environment, Health, and Safety) system to ensure occupational health and environmental safety. Serving renowned domestic and international pharmaceutical enterprises, Taxus Pharmaceutical has earned widespread market recognition and client acclaim.